Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Oxybutynin Chloride
United Therapeutics Europe Ltd
Breast Carcinoma
1 trial -
Ozanimod, Ozanimod
Celgene Europe Limited
Ulcerative colitis
1 trial -
Ozanimod, Ozanimod
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
Ozanimod, Ozanimod, Ozanimod
Bristol-Myers Squibb Australia Pty Ltd
Moderately to Severely Active Ulcerative Colitis
1 trial -
P1101
PharmaEssentia
Polycythemia Vera (PV)
1 trial -
PACLITAXEL , Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, GEMCITABINE, FOLINIC ACID, FLUOROURACIL
CERO THERAPEUTICS HOLDINGS, INC.
Metastatic pancreatic cancer
1 trial -
PACLITAXEL, CISPLATIN, CARBOPLATIN, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, PEMETREXED, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED
CERO THERAPEUTICS HOLDINGS, INC.
Non small cell lung cancer
1 trial -
PACLITAXEL, LEUPRORELIN, GOSERELIN, TRIPTORELIN, EPIRUBICIN, TRIPTORELIN, EXEMESTANE, RIBOCICLIB, CYCLOPHOSPHAMIDE, LETROZOLE, DOXORUBICIN, GOSERELIN, LEUPRORELIN, ANASTROZOLE, PACLITAXEL ALBUMIN-BOUND, DOCETAXEL
Ningbo Cancer Hospital
Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy
1 trial -
PDS Implant with Ranibizumab 100 mg/mL
Hoffmann-La Roche
Neovascular Age-Related Macular Degeneration
1 trial -
PEGASPARGASE
Pari Pharma GmbH
This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL
1 trial -
PEGCETACOPLAN (APL-2)
Apellis Europe B.V.
Geographic Atrophy Secondary to Age-related Macular Degeneration
1 trial -
PEMBROLIZUMAB
Ningbo Cancer Hospital
Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.
1 trial -
PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent
Eikon Therapeutics
Advanced Melanoma
1 trial -
PEMETREXED , GEMCITABINE , PACLITAXEL , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion.
Partner Therapeutics Limited
Stage IIB-IIIB (N2) resectable non small cell lung cancer
1 trial -
PF-07275315 dose 1
Pfizer
Moderate to Severe Chronic Obstructive Pulmonary Disease
1 trial -
PF614 capsule
Ensysce Biosciences
Postoperative Pain, Acute
1 trial -
PGET
Atrium Therapeutics
Osteoarthritis
1 trial -
PH94B
Vistagen Therapeutics
Social Anxiety Disorder
1 trial -
PH94B Nasal Spray
Vistagen Therapeutics
Social Anxiety Disorder
2 trials -
PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , NEGABAN 2 g, poudre pour solution injectable/pour perfusion, MEROPENEM ARROW 1 g, poudre pour solution injectable / pour perfusion
Pari Pharma GmbH
patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection
1 trial -
PIPERACILLINE TAZOBACTAM VIATRIS 4 g/0,5 g, poudre pour solution pour perfusion, CEFAZOLIN, Placebo de Cefazoline / Piperaciline / Tazobactam
Pari Pharma GmbH
Excision-autograft surgery in burn patient
1 trial -
PL1 - Placebo to match losmapimod tablets are tablets for oral administration and visually match the active losmapimod tablets, 15 mg., Losmapimod
Fulcrum Therapeutics
Facioscapulohumeral Muscular Dystrophy (FSHD)
1 trial -
PL2200 Aspirin Capsules
Protalix BioTherapeutics
Diabetes Mellitus, Type 2
2 trials -
PLACEBO, Nicetile 500 mg polvere per soluzione orale
Istituto Gentili S.r.l.
amyotrophic lateral sclerosis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources